Patients with larger tumors (>3 cm) or lymph node metastasis exhibited significantly higher FHL2 levels compared to those with smaller tumors or no metastasis (Fig. 2, C and D). This evidence concerns the gene FHL2 and metastatic malignant neoplasm in the lymph nodes.